Abstract:MM is an incurable B cell neoplasm, which is characterized by the clonal proliferation of plasma cells in the bone marrow (BM), accounts for approximately 10% of hematological malignancies. Insulin-like growth factor-1 (IGF-1) is a vital proliferation factor in myeloma cells, recent researches demonstrated that it may be involved in MM cell metastasis. In last decade, studies have demonstrated that IGF-1 induces epithelial-mesenchymal transition (EMT), which has been tightly correlated with increased motility and invasive capacity in several cancers including gastric cancer, hepatocellular carcinoma, and melanoma. However, it remains unclear whether IGF-1 induces EMT and promote myeloma progression. In this study, we firstly observed the morphology of the myeloma cell line Karpas707 changed from tight polygon to loose spindle, a mesenchymal phenotype after treated with IGF-1 (50 ng/ml) after 72h. We supposed IGF-1 may induced EMT in myeloma cells. Furthermore, when serum-starved MM cell lines RPMI8226 and MM1.S were stimulated with 50ng/mL of IGF-1, we found that the expression of mesenchymal features was significantly upregulated in a time-dependent manner, as determined by both flow cytometry analysis and western blotting. Next we confirmed that IGF-1 can activate the PI3K/Akt signaling pathway by inducing the phosphorylation of Akt in MM cells. To investigated whether PI3K/Akt signaling pathway involved in the IGF-1 mediated EMT, we blocked PI3K/Akt signaling pathway using Akt inhibitor MK2206 in IGF-1 treated MM.1S cells. We found MK2206 reversed these changes of EMT markers. Moreover, we found the IGF-1-induced EMT promotes myeloma progression, including migration, invasion, adhesion and clone formation in MM cells, using transwell migration and invasion assay, cell adhesion assay, colony formation assay and flow cytometry. Furthermore, to further validate IGF-1-induced EMT promote MM progression, we knocked down mesenchymal marker vimentin using siRNA in MM.1S cells (VIM k/d cells). We detected that these function IGF-1 plays in myeloma was impaired in Vim k/d cells, indicating that IGF-1-induced EMT promotes MM progression. Finally, we validated that IGF1 expression is aberrantly upregulated and correlated with the expression of the EMT markers by analyzing the mRNA data of BM samples from normal donors and patients in different stages of plasma cell neoplasm from the GEO database. Taken together, these data demonstrate that the mesenchymal phenotype induced by IGF1 contributes to MM progression via PI3K/Akt pathway. Disclosures No relevant conflicts of interest to declare.

Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis

Reelin Promotes the Adhesion and Drug Resistance of Multiple Myeloma Cells Via Integrin Β1 Signaling and STAT3

Epigenetic Regulation of Reelin Expression in Multiple Myeloma

Reelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin β1 signaling.

Reelin Promotes Adhesion Of Multiple Myeloma Cells To Bone Marrow Stromal Cells Via Integrin Beta 1 Signaling

Expression of Extracellular Matrix Protein Reelin in Patients with Multiple Myeloma and Its Relationship with Prognosis

The Potential Role of the Extracellular Matrix Glycoprotein Reelin in Glioblastoma Biology

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma

Myeloma-specific Superenhancers Affect Genes of Biological and Clinical Relevance in Myeloma.

Intratumor Heterogeneity of MIF Expression Correlates with Extramedullary Involvement of Multiple Myeloma.

Enhanced Expression of Glycolytic Enzymes and Succinate Dehydrogenase Complex Flavoprotein Subunit A by Mesothelin Promotes Glycolysis and Mitochondrial Respiration in Myeloblasts of Acute Myeloid Leukemia

Functional Heterogeneity of Reelin in the Oral Squamous Cell Carcinoma Microenvironment

Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth

CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation

Interference with PLA2G16 promotes cell cycle arrest and apoptosis and inhibits the reprogramming of glucose metabolism in multiple myeloma cells by modulating the Hippo/YAP signaling pathway

Pgc1 Beta Regulates Multiple Myeloma Tumor Growth Through Ldha-Mediated Glycolytic Metabolism

Long Noncoding RNA CRNDE Promotes Multiple Myeloma Cell Growth by Suppressing Mir-451.

High Levels of Serum IL-10 Indicate Disease Progression, Extramedullary Involvement, and Poor Prognosis in Multiple Myeloma.

IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition

Insulin-like Growth Factor-1-Induced Epithelial-Mesenchymal Transition Promotes Multiple Myeloma Progression

The role of SH3GL3 in myeloma cell migration/invasion, stemness and chemo-resistance